Wolverine Trading
NKTR icon

Wolverine Trading’s Nektar Therapeutics NKTR Stock Holding History

Wolverine Trading’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$4.33M Buy
73,500
+23,500
+47% +$778K ﹤0.01% 1491
2025
Q2 		$1.29M Buy
+50,000
New +$561K ﹤0.01% 2074
2022
Q3 		– Sell
-967
Closed -$57K – 5090
2022
Q2 		$57K Sell
967
-4,980
-84% -$314K ﹤0.01% 4035
2022
Q1 		$497K Buy
+5,947
New +$880K ﹤0.01% 3233
2021
Q3 		– Sell
-2,840
Closed -$742K – 6720
2021
Q2 		$742K Sell
2,840
-607
-18% -$168K ﹤0.01% 3168
2021
Q1 		$1.01M Buy
3,447
+2,294
+199% +$714K ﹤0.01% 2751
2020
Q4 		$310K Sell
1,153
-274
-19% -$70.8K ﹤0.01% 3716
2020
Q3 		$361K Sell
1,427
-646
-31% -$203K ﹤0.01% 3161
2020
Q2 		$697K Sell
2,073
-14
-0.7% -$4.37K ﹤0.01% 2377
2020
Q1 		$565K Sell
2,087
-1,273
-38% -$394K ﹤0.01% 2523
2019
Q4 		$1.05M Buy
3,360
+1,493
+80% +$433K ﹤0.01% 2367
2019
Q3 		$501K Buy
1,867
+480
+35% +$176K ﹤0.01% 2625
2019
Q2 		$740K Buy
1,387
+607
+78% +$304K ﹤0.01% 2319
2019
Q1 		$393K Sell
780
-273
-26% -$162K ﹤0.01% 3045
2018
Q4 		$531K Sell
1,053
-1,154
-52% -$697K ﹤0.01% 2570
2018
Q3 		$2.02M Buy
2,207
+1,414
+178% +$1.21M ﹤0.01% 1658
2018
Q2 		$1.26M Hold
793
– – ﹤0.01% 2018
2018
Q1 		$1.26M Sell
793
-1,667
-68% -$2.15M ﹤0.01% 2018
2017
Q4 		$2.2M Sell
2,460
-173
-7% -$102K 0.01% 1467
2017
Q3 		$948K Buy
2,633
+133
+5% +$41.6K ﹤0.01% 1962
2017
Q2 		$725K Buy
+2,500
New +$722K ﹤0.01% 2057
2017
Q1 		– Sell
-3,600
Closed -$663K – 4758
2016
Q4 		$663K Buy
3,600
+453
+14% +$92.1K ﹤0.01% 2312
2016
Q3 		$800K Buy
3,147
+2,427
+337% +$625K ﹤0.01% 2103
2016
Q2 		$151K Buy
+720
New +$161K ﹤0.01% 3449

Other funds holding NKTR

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wolverine Trading's NKTR Position: Q3 2025 in Review

Wolverine Trading increased its Nektar Therapeutics (NKTR) stake by 283% in Q3 2025, buying an estimated $1.41M and bringing the position to 57,758 shares worth $3.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1716.

Wolverine Trading first reported a position in NKTR in Q3 2016 and has held it in 20 quarters since. 154 funds tracked by Wall St. Rank hold NKTR as of Q3 2025.

  • Wolverine Trading held 57,758 shares of Nektar Therapeutics worth $3.4M as of Q3 2025.
  • Wolverine Trading bought 42,686 Nektar Therapeutics shares in Q3 2025, an estimated $1.41M.
  • Nektar Therapeutics made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #1716 holding.
  • Wolverine Trading first reported a position in Nektar Therapeutics in Q3 2016 and has held it in 20 quarters since.
  • 154 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.